Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 35, 502-505, March 1, 1975]
© 1975 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Duuren, B. L.
Right arrow Articles by Melchionne, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Duuren, B. L.
Right arrow Articles by Melchionne, S.

The Effect of Aging and Interval between Primary and Secondary Treatment in Two-Stage Carcinogenesis on Mouse Skin1

B. L. Van Duuren, A. Sivak, C. Katz, I. Seidman and S. Melchionne

Laboratory of Organic Chemistry and Carcinogenesis, Institute of Environmental Medicine [B. L. V. D., A. S., C. K., S. M.], and Department of Pathology [I. S.], New York University Medical Center, New York, New York, 10016

Two-stage carcinogenesis experiments on mouse skin (female ICR/Ha Swiss mice) were done by initiating mice at three age levels (6, 44, and 56 weeks) and promoting after a 2-week interval. In another series, mice were initiated at age 6 weeks, and three time intervals (2, 36, and 56 weeks) were used between initiation and promotion. The initiating agent was 7,12-dimethylbenz(a)anthracene and the promoting agent was phorbol myristate acetate in all experiments. The results showed a general decrease in tumor production with increasing age at the time of promotion. However, the initiating effect persisted even when the interval between initiation and promotion was 56 weeks.

1 This work was supported by USPHS Grants CA-15095 from the National Cancer Institute and ES-00260 from the National Institutes of Environmental Health Sciences.

Received 8/ 5/74. Accepted 11/20/74.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Rubin
Cell-cell contact interactions conditionally determine suppression and selection of the neoplastic phenotype
PNAS, April 29, 2008; 105(17): 6215 - 6221.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. V. Popova, K. A. Teti, K. Q. Wu, and R. J. Morris
Identification of two keratinocyte stem cell regulatory loci implicated in skin carcinogenesis
Carcinogenesis, March 1, 2003; 24(3): 417 - 425.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
Z. Qin, H.-J. Kim, J. Hemme, and T. Blankenstein
Inhibition of Methylcholanthrene-induced Carcinogenesis by an Interferon {gamma} Receptor-dependent Foreign Body Reaction
J. Exp. Med., June 3, 2002; 195(11): 1479 - 1490.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. StJ. Battalora, J. W. Spalding, C. J. Szczesniak, J. E. Cape, R. J. Morris, C. S. Trempus, C. D. Bortner, B. M. Lee, and R. W. Tennant
Age-dependent skin tumorigenesis and transgene expression in the Tg.AC (v-Ha-ras) transgenic mouse
Carcinogenesis, April 1, 2001; 22(4): 651 - 659.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1975 by the American Association for Cancer Research.